Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (398)	12/18/2003 11:23:03 AM
From: Icebrg	Read Replies (1) \| Respond to of 824

Thanks Wilder I remember C5 has always been negative to the drug and its prospects. Perhaps more the latter than the former. It would be interesting to know why XOMA/MLNM thinks this is an interesting path to pursue. Or I should perhaps rather say "Why XOMA want to try their hands on this matter. MLNM has opted out and have a possibility to opt in again after completion of phase II trials. In November 2001, we entered into a collaboration agreement with XOMA Ltd., or XOMA, providing for the development by XOMA of two biotherapeutic agents of ours in the cardiovascular disease area. The agreement provides for payment of associated costs by XOMA through completion of Phase II trials of these agents, commercialization of the products by us after successful Phase II trials and the choice by XOMA to further participate in the development program and share in profits or to receive future milestone and royalty payments from us. Erik